Skip to content
Saunatica

Peptide

Epitalon (Epithalon)

  • Peptide
  • Circadian & aging research
  • Not FDA-approved

Epitalon is a four-amino-acid synthetic peptide studied in relation to circadian biology, telomeres, and aging. Human evidence is small, indirect, and does not show that it improves insomnia or extends life.

The basics

What is it?

Epitalon, also spelled Epithalon, is the synthetic four-amino-acid peptide Ala-Glu-Asp-Gly, often shortened to AEDG. It was designed from the amino-acid composition of epithalamin, a mixture of peptides extracted from bovine pineal glands. Epitalon and epithalamin are different substances. Older publications sometimes blur their names, so findings about the extract cannot automatically be attributed to Epitalon.

Why it comes up

What are people interested in it for?

  • Melatonin and circadian biology
  • Sleep research
  • Telomerase and telomere research
  • Cellular aging
  • Animal lifespan and tumor research
  • Retinal-disease research

These are research topics, not established human benefits. Much of the frequently cited longevity literature involves animals, cells, or the different pineal extract epithalamin.

Evidence

What does the research show?

Animal evidence

Female rhesus-monkey experiments reported changes in evening melatonin or cortisol measurements but did not measure sleep behavior or brain-wave sleep outcomes. Several fixed-dose studies from one research group examined survival and spontaneous tumors in female mice; FDA found those models too limited to establish genotoxicity, cancer risk, or long-term safety. A 2025 study reported telomere-length changes through telomerase-related or alternative pathways in normal and cancer cell lines. That was laboratory work, not a human trial, and it does not show clinical anti-aging or longevity effects.

Human evidence

The clearest randomized evidence comes from one 2021 biomarker population of 75 women, many of whom worked night shifts. Thirty-five women with age-normal measurements formed a reference group. Forty women with low measurements were randomized: 20 received placebo and 20 received AEDG for 20 days. The reports measured a urine melatonin metabolite and clock-gene expression in blood cells, not insomnia symptoms, sleep duration, awakenings, or other clinical sleep outcomes. Two publications appear to report different endpoints from this same population, not two independent trials. A separate older retinitis-pigmentosa report involved 162 patients according to a later review, but it was not a modern large randomized, masked trial and did not study sleep, aging, or longevity. There is no randomized trial showing benefit for insomnia, longer life, slower aging, or clinical telomere outcomes.

Evidence grade

No formal GRADE assessment was found. One small randomized biomarker study exists, but there is no controlled clinical evidence for insomnia or longevity. Overall human evidence is very low or insufficient; this is not a published letter grade.

Unknowns and risks

What about safety?

The small biomarker study did not provide usable safety reporting, and FDA found no dedicated clinical safety or pharmacokinetic study. FAERS and food-complaint searches through December 2025 found no cases, but incomplete reporting cannot establish safety. FDA found no adequate acute or repeat-dose toxicity program, developmental or reproductive program, or two-year carcinogenicity study. Potential concerns include impurities, aggregation, immune reactions, sterility, endotoxins, and inconsistent product naming. Because laboratory studies have reported telomerase-related effects, FDA also identified a theoretical concern that chronic exposure could affect abnormal cells. That is not proof that Epitalon causes cancer; the actual human risk is unknown.

Regulatory status

Is it legal / FDA-approved?

  1. 1Epitalon free base and acetate are not FDA-approved, have no applicable USP/NF drug-substance monograph, and are not components of an FDA-approved drug.
  2. 2Its former 503A Category 2 nomination was withdrawn. Epitalon now appears under substances nominated but withdrawn, not as current Category 2, and it is not Category 1.
  3. 3Epitalon is not on the final 503A Bulks List. The withdrawn nomination does not authorize compounding or grant Category 1 enforcement discretion.
  4. 4On July 24, 2026, PCAC reviews Epitalon for insomnia. FDA staff proposes not adding the free base or acetate form. The committee's advice is nonbinding, and FDA has not made its final decision.
  5. 5An orphan-drug designation for retinitis pigmentosa was granted in 2010 and later withdrawn or revoked in 2016. Orphan designation was never marketing approval.
  6. 6FDA enforcement involving Tailor Made Compounding identified Epitalon among unapproved compounded drug products.
  7. 7Online "research use only" labeling is seller marketing, not approval or permission for human administration.

A practical checklist

Questions to ask a licensed provider

  • Is the evidence about synthetic Epitalon or the different extract called epithalamin?
  • Did the human study measure clinical sleep or health outcomes, or only biomarkers?
  • What evidence supports the particular reason I'm considering it?
  • What is known about long-term safety and the unanswered telomerase questions?
  • What is its current FDA and compounding status?
  • How would product identity, purity, sterility, endotoxins, and aggregates be checked?
  • Are there approved options with stronger human evidence?